Trial Profile
A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Jul 2021
Price :
$35
*
At a glance
- Drugs SIILPCV10 (Primary) ; Haemophilus influenzae-pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- 01 Jun 2021 Primary endpoint (Safety, Tolerability) has been met according to the results published in The Lancet Infectious Diseases
- 01 Jun 2021 Primary endpoint (Safety, Tolerability) has been met according to the results published in The Lancet Infectious Diseases
- 01 Jun 2021 Primary endpoint (EPI non-interference) has been met according to the results published in The Lancet Infectious Diseases